ES2535928T3 - Método para inhibir Clostridium difficile mediante la administración de oritavancina - Google Patents

Método para inhibir Clostridium difficile mediante la administración de oritavancina Download PDF

Info

Publication number
ES2535928T3
ES2535928T3 ES08830916.6T ES08830916T ES2535928T3 ES 2535928 T3 ES2535928 T3 ES 2535928T3 ES 08830916 T ES08830916 T ES 08830916T ES 2535928 T3 ES2535928 T3 ES 2535928T3
Authority
ES
Spain
Prior art keywords
difficile
oritavancin
spore
glycopeptide antibiotic
spores
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08830916.6T
Other languages
English (en)
Spanish (es)
Inventor
Mark Harvey Wilcox
Simon Baines
Dario Lehoux
Thomas R. Parr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Medicines Co
Original Assignee
The Medicines Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Medicines Co filed Critical The Medicines Co
Application granted granted Critical
Publication of ES2535928T3 publication Critical patent/ES2535928T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pest Control & Pesticides (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES08830916.6T 2007-09-12 2008-09-11 Método para inhibir Clostridium difficile mediante la administración de oritavancina Active ES2535928T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97176607P 2007-09-12 2007-09-12
US971766P 2007-09-12
PCT/US2008/075949 WO2009036121A1 (en) 2007-09-12 2008-09-11 Method of inhibiting clostridium difficile by administration of oritavancin

Publications (1)

Publication Number Publication Date
ES2535928T3 true ES2535928T3 (es) 2015-05-19

Family

ID=40452464

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08830916.6T Active ES2535928T3 (es) 2007-09-12 2008-09-11 Método para inhibir Clostridium difficile mediante la administración de oritavancina

Country Status (9)

Country Link
US (3) US8518873B2 (enExample)
EP (1) EP2195004B1 (enExample)
JP (1) JP5591112B2 (enExample)
CN (1) CN102316885A (enExample)
AU (1) AU2008298987B2 (enExample)
CA (1) CA2699550C (enExample)
EA (1) EA017564B1 (enExample)
ES (1) ES2535928T3 (enExample)
WO (1) WO2009036121A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518873B2 (en) * 2007-09-12 2013-08-27 The Medicines Company Method of inhibiting clostridium difficile by administration of oritavancin
ES2884673T3 (es) * 2008-04-08 2021-12-10 Melinta Therapeutics Inc Oritavancina para inhibir y tratar biopelículas
PT2424559T (pt) * 2009-04-28 2024-04-30 Melinta Therapeutics Llc Métodos de tratamento de infeções bacterianas utilizando oritavancina
JP5986416B2 (ja) * 2012-04-11 2016-09-06 花王株式会社 皮膚外用剤
MX2015006491A (es) 2012-11-23 2015-12-03 Seres Health Inc Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas.
EP2951283A4 (en) 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Compositions and methods
MX369877B (es) * 2013-02-04 2019-11-25 Seres Therapeutics Inc Composiciones y metodos.
JP2016519664A (ja) 2013-03-15 2016-07-07 セレス セラピューティクス インコーポレイテッド ネットワークを基にした微生物組成物及び方法
MX367109B (es) 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
JP6553074B2 (ja) * 2014-10-14 2019-07-31 アーゼッド・エレクトロニック・マテリアルズ（ルクセンブルグ）ソシエテ・ア・レスポンサビリテ・リミテ レジストパターン処理用組成物およびそれを用いたパターン形成方法
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
CA3014294A1 (en) 2016-02-18 2017-08-24 Melinta Therapeutics, Inc. Oritavancin formulations
CN107325159A (zh) * 2016-04-29 2017-11-07 中国科学院上海药物研究所 一类万古霉素衍生物、其制备方法、药物组合物和用途
MX388732B (es) 2016-05-09 2025-03-20 Xellia Pharmaceuticals Aps Formulaciones de antibioticos glicopeptidicos estabilizados
BR112020002992A2 (pt) 2017-08-14 2020-08-18 Seres Therapeutics, Inc. composições e métodos para tratamento de doença colestática
JP2021501185A (ja) 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法
CA3109900A1 (en) * 2018-08-17 2020-02-20 Universidad Andres Bello Method and pharmacological composition for the prevention of recurrent infections caused by clostridium difficile
KR102444119B1 (ko) * 2020-04-22 2022-09-16 주식회사 인트론바이오테크놀로지 클로스트리디오이데스 디피실리 균에 대하여 용균 활성을 갖는 항균단백질 cdl200

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2961184B2 (ja) * 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
GB0212622D0 (en) * 2002-05-31 2002-07-10 Natural Technologies Group Ltd Bacterial transforming agent
AU2003240545A1 (en) * 2002-06-06 2003-12-22 Therapeutics Corporation Genome Use of ramoplanin to treat diseases associated with the use of antibiotics
ATE448775T1 (de) * 2002-08-29 2009-12-15 Activbiotics Pharma Llc Rifalazil zur behandlung von infektionen mit clostridium difficile
CN1918172B (zh) * 2003-12-23 2011-09-14 活跃生物工艺学公司 利福霉素类似物及其用途
WO2007092582A2 (en) * 2006-02-08 2007-08-16 Biosynexus Incorporated Neutralization of bacterial spores
GB0714030D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
US8518873B2 (en) * 2007-09-12 2013-08-27 The Medicines Company Method of inhibiting clostridium difficile by administration of oritavancin

Also Published As

Publication number Publication date
EA201000383A1 (ru) 2010-10-29
EP2195004A1 (en) 2010-06-16
CA2699550C (en) 2020-08-18
US8518873B2 (en) 2013-08-27
BRPI0816662A2 (pt) 2017-06-13
US20140100157A1 (en) 2014-04-10
US8629100B2 (en) 2014-01-14
US20130310308A1 (en) 2013-11-21
EP2195004B1 (en) 2015-04-01
EP2195004A4 (en) 2011-12-28
AU2008298987B2 (en) 2013-12-05
CA2699550A1 (en) 2009-03-19
JP2010539179A (ja) 2010-12-16
US20100311646A1 (en) 2010-12-09
WO2009036121A1 (en) 2009-03-19
JP5591112B2 (ja) 2014-09-17
EA017564B1 (ru) 2013-01-30
CN102316885A (zh) 2012-01-11
AU2008298987A1 (en) 2009-03-19
US9220749B2 (en) 2015-12-29

Similar Documents

Publication Publication Date Title
CA2699550C (en) Method of inhibiting clostridium difficile by administration of oritavancin
US10857164B2 (en) Halogenated salicylanilides for treating Clostridium infections
ES2884673T3 (es) Oritavancina para inhibir y tratar biopelículas
ES2994966T3 (en) Single doses of oritavancin for treating or preventing a bacterial infection
KR20010022237A (ko) 리소스타핀을 단독 또는 항생제와의 조합으로 포함하는포도상구균 감염 치료용 약제학적 조성물
CA2664444C (en) Use of oritavancin for prevention and treatment of anthrax
US20150273025A1 (en) Apyrase treatments
CN107847502A (zh) 抗菌组合物
US9913854B2 (en) Methods and compositions for reducing the proliferation of gram positive bacteria
ES2902456T3 (es) Composiciones farmacéuticas que comprenden agentes antibacterianos
EP3038615A2 (en) Methods for treating bacterial infections using oritavancin and polymyxins
ES2905979T3 (es) Composiciones antibacterianas
BRPI0816662B1 (pt) Método in vitro para inibir crescimento de esporo de c. difficile
RU2813568C2 (ru) Антибактериальные композиции
AU2013202360B2 (en) Methods of treatment using single doses of oritavancin